StoneX Group Inc. Takes $981,000 Position in AngioDynamics, Inc. (NASDAQ:ANGO)

StoneX Group Inc. bought a new position in AngioDynamics, Inc. (NASDAQ:ANGO) in the fourth quarter, according to its most recent filing with the SEC. The firm bought 107,083 shares of the medical instruments supplier’s stock, valued at approximately $981,000. StoneX Group Inc. owned approximately 0.26% of AngioDynamics as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the stock. SBI Securities Co. Ltd. acquired a new stake in shares of AngioDynamics during the fourth quarter worth $28,000. R Squared Ltd acquired a new stake in AngioDynamics during the 4th quarter worth about $49,000. US Bancorp DE grew its stake in AngioDynamics by 1,938.0% during the 4th quarter. US Bancorp DE now owns 6,705 shares of the medical instruments supplier’s stock valued at $61,000 after purchasing an additional 6,376 shares during the last quarter. Quarry LP increased its holdings in shares of AngioDynamics by 40.9% in the third quarter. Quarry LP now owns 8,518 shares of the medical instruments supplier’s stock valued at $66,000 after purchasing an additional 2,471 shares during the period. Finally, SG Americas Securities LLC raised its stake in shares of AngioDynamics by 21.3% in the fourth quarter. SG Americas Securities LLC now owns 16,102 shares of the medical instruments supplier’s stock worth $147,000 after purchasing an additional 2,832 shares during the last quarter. Hedge funds and other institutional investors own 89.43% of the company’s stock.

AngioDynamics Stock Performance

Shares of ANGO opened at $9.66 on Wednesday. The company has a market capitalization of $390.90 million, a P/E ratio of -1.72 and a beta of 0.56. The business’s 50-day moving average is $10.30 and its two-hundred day moving average is $8.84. AngioDynamics, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $13.50.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.07. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The company had revenue of $72.90 million during the quarter, compared to analysts’ expectations of $70.93 million. During the same period last year, the business earned ($0.05) earnings per share. AngioDynamics’s quarterly revenue was down .1% on a year-over-year basis. Analysts forecast that AngioDynamics, Inc. will post -0.37 EPS for the current year.

Insider Buying and Selling

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 4,060 shares of AngioDynamics stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $12.31, for a total value of $49,978.60. Following the completion of the transaction, the senior vice president now owns 41,817 shares of the company’s stock, valued at approximately $514,767.27. The trade was a 8.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 5.40% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Separately, HC Wainwright upped their target price on AngioDynamics from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Friday, January 10th.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.